Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Northland Capital Markets Maintains Outperform on Cardlytics, Lowers Price Target to $7

Author: Benzinga Newsdesk | August 08, 2024 01:25pm
Northland Capital Markets analyst Luke Horton maintains Cardlytics (NASDAQ:CDLX) with a Outperform and lowers the price target from $14 to $7.

Posted In: CDLX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist